Clinical investigations of antiobesity drugs

Appetite and Body Weight

Volumn , Issue , 2007, Pages 337-355

  Wilding, John ^a  

^a University Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865494008     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370633-1/50014-1     Document Type: Chapter

References (87)

1. Abenhaim I., Moride Y., Brenot F. AΠΠΠέτΙτέ σνΠΠεσσαντ δνγσ ανδ τηε ισΚ o ΠιμαΨ ΠνλμoναΨ ηΨπετενσιoν. N. Engl. J. Med. 1996, 335:609-616.
2. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 1996, 335:609-616.
3. Adrian T.E., Allen J.M., Bloom S.R., Ghatei M.A., Rosser M.N., Roberts G.W., et al. Neuropeptide Y distribution in human brain. Nature 1983, 308:584-586.
4. Adrian T.E., Ferri G.L., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985, 89:1070-1077.
5. Allen Y.S., Adrian T.E., Allen J.M., Tatemoto K., Crow T.J., Bloom S.R., et al. Neuropeptide Y distribution in the rat brain. Science 1983, 221:877-879.
6. Apfelbaum M., Vague P., Ziegler O., Hanotin C., Thomas F., Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am. J. Med. 1999, 106:179-184.
7. Asakawa A., Inui A., Kaga T., Yuzuriha H., Nagata T., Ueno N., et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001, 120:337-345.
8. Astrup A., Breum L., Toubro S., Hein P., Quaade F. The effect and safety of an ephedrine caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet-a double-blind trial. Int. J. Obes. 1992, 16:269-277.
9. Ballinger A., Mcloughlin L., Medbak S., Clark M. Cholecystokinin is a satiety hormone in humans at physiological post-prandial plasma concentrations. Clin. Sci. (Colch.) 1995, 89:375-381.
10. TM) on appetite and eating behaviour and the long-term therapeutic outcome. Int. J. Obes. 2003, 27:693-700.
11. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 2003, 349:941-948.
12. Borgstrom B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim. Biophys. Acta 1988, 962:308-316.
13. Borowsky B., Durkin M.M., Ogozalek K., Marzabadi M.R., DeLeon J., Heurich R., et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med. 2002, 8:825-830.
14. Bray G.A. Drug treatment of obesity. Best Pract. Res. Clin. Endocrinol. Metab. 1999, 13:131-148.
15. Bray G.A., Ryan D.H., Gordon D., Heidingsfelder S., Macchiavelli R., Wilson K. Doubleblind randomized trial of sibutramine in overweight subjects. Am. J. Clin. Nutr. 1995, 61:912.
16. Bray G.A., Ryan D.H., Gordon D., Heidingsfelder S., Cerise F., Wilson K. Double-blind randomized placebo-controlled trial of sibutramine. Obes. Res. 1996, 4:263-270.
17. Bray G.A., Blackburn G.L., Ferguson J.M., Greenway F.L., Jain A.K., Mendel C.M., et al. Sibutramne produces dose-related weight loss. Obes. Res. 1999, 7:189-198.
18. Brenot F., Herve P., Petitpretz P., Parent F., Duroux P., Simonneau G. Primary pulmonary-hypertension and fenfluramine use. Br. Heart J. 1993, 70:537-541.
19. Broom I., Wilding J., Stott P., Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. Int. J. Clin. Pract. 2002, 56:494-499.
20. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
21. Caffry E.W., Kissileff H.R., Thornton J.C. Assessment of the effects of phenylpropanolamine on appetite and food intake. Pharmacol. Biochem. Behav. 1987, 26:321-325.
22. Carvajal A., del Pozo J.G., de Diego I.M., de Castro A.M.R., Velasco A. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis. Methods Find Exp. Clin. Pharmacol. 2000, 22:285-290.
23. Clapham J.C. Fat oxidation in obesity: druggable or risky enterprise?. Idrugs 2004, 7:238-242.
24. Clapham J.C. Treating obesity: pharmacology of energy expenditure. Curr. Drug Targets 2004, 5:309-323.
25. Clark J.T., Kalra P.S., Crowley W.R., Kalra S.P. Neuropeptide Y and pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984, 115:427-429.
26. Cohen M.A., Ellis S.M., Le Roux C.W., Batterham R.L., Park A., Patterson M., et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. 2003, 88:4696-4701.
27. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann. Intern. Med. 2005, 143:380-385.
28. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 1997, 337:581-588.
29. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001, 50:1714-1719.
30. Dakin C.L., Gunn I., Small C.J., Edwards C.M.B., Hay D.L., Smith D.M., et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001, 142:4244-4250.
31. Daniels A.J., Grizzle M.K., Wiard R.P., Matthews J.E., Heyer D. Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regul Rept. 2002, 106:47-54.
32. Davidson M. A 2 year, U.S., randomized, controlled study of orlistat, a gastrointestinal lipase inhibitor, for obesity treatment. JAMA 1997, 96:4119.
33. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
34. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 2005, 353:2121-2134.
35. Douketis J.D., Macie C., Thabane L., Williamson D.F. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int. J. Obes. 2005, 29:1153-1167.
36. Dourish C.T., Rycroft W., Iversen S.D. Postponement of satiety by blockade of cholecystokinin (CCK-B) receptors. Science 1989, 245:1509-1511.
37. Drent M.L., Larsson I., Williamolsson T., Quaade F., Czubayko F., Vonbergmann K., et al. Orlistat (Ro-18-0647), a lipase inhibitor, in the treatment of human obesity-a multiple-dose study. Int. J. Obes. 1995, 19:221-226.
38. Dumont Y., Thakur M., Beck-Sickinger A., Fournier A., Quirion R. Characterization of a new neuropeptide Y Y5 agonist radioligand: [I-125] [cPP(1-7), NPY(19-23), Ala(31), Aib(32), Gln(34)] hPP. Neuropeptides 2004, 38:163-174.
39. Dyke H.J., Ray N.C. Recent developments in the discovery of MCH-1R antagonists for the treatment of obesity-an update. Expert Opin. Ther. Pats. 2005, 15:1303-1313.
40. Edwards C.M.B., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab. 2001, 281:E155-E161.
41. English P.J., Ghatei M.A., Malik I.A., Bloom S.R., Wilding J.P.H. food fails to suppress ghrelin levels in obese humans. J. Clin. Endocrinol. Metab. 2002, 87:2984-2987.
42. Erickson J.C., Clegg K.E., Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996, 381:415-418.
43. Gadde K.M., Franciscy D.M., Wagner H.R., Krishnan K.R.R. Zonisamide for weight loss in obese adults-A randomized controlled trial. JAMA 2003, 289:1820-1825.
44. Gary-Bobo M., Elachouri G., Scatton B., Le Fur G., Oury-Donat F., Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol. Pharmacol. 2006, 69:471-478.
45. Guerciolin R. Mode of action of orlistat. Int. J. Obes. 1997, 21:S12-S23.
46. Guy-Grand B., Apfelbaum M., Crepaldi G., Gries A., Lefebvre P., Turner P. International trial of long term dexfenfluramine in obesity. Lancet 1989, 1142-1145.
47. Hanefeld M., Sachse G. The effects of orlistat on body weight and glycaemic control in over-weight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2002, 4:415-423.
48. Hansen D.L., Toubro S., Stock M.J., Macdonald I.A., Astrup A. Thermogenic effects of sibutramine in humans. Am. J. Clin. Nutr. 1998, 68:1180-1186.
49. Hollander P.A., Elbein S.C., Hirsch I.B., Kelley D., McGill J., Taylor T., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes-A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288-1294.
50. Holst B., Cygankiewicz A., Jensen T.H., Ankersen M., Schwartz T.W. High constitutive signaling of the ghrelin receptor-Identification of a potent inverse agonist. Mol. Endocrinol. 2003, 17:2201-2210.
51. Hwa J.J., Witten M.B., Williams P., Ghibaudi L., Gao J., Salisbury B.G., et al. Activation of the NPYY5 receptor regulates both feeding and energy expenditure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1999, 277:R1428-R1434.
52. James W.P.T., Astrup A., Finer N., Hilsted J., Kopelman P., Rossner S., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000, 356:2119-2125.
53. Kalra S.P., Dube M.G., Sahu A., Phelps C.P. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:10931-10935.
54. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., et al. Synthetic exendin-4 (Exenatide) significantly reduces postprandial and tasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003, 88:3082-3089.
55. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-17-36: a physiological incretin in man. Lancet 1987, 2:1300-1304.
56. Kyrkouli S.E., Stanley B.G., Leibowitz S.F. Galanin: stimulation of feeding induced by medial hypothalamic injection of this novel peptide. Eur. J. Pharmacol. 1986, 122:159-160.
57. Lambert P.D., Wilding J.P.H., Al-Dokhayel A.A.M., Bohuon C., Comoy E., Gilbey S.G., et al. A role for neuropeptide Y, dynorphin and noradrenaline in the central control of food intake after food deprivation. Endocrinology 1993, 133:29-32.
58. Lambert P.D., Wilding J.P., Turton M.D., Ghatei M.A., Bloom S.R. Effect of food deprivation and streptozotocin-induced diabetes on hypothalamic neuropeptide Y release as measured by a radioimmunoassay-linked microdialysis procedure. Brain Res. 1994, 656:135-140.
59. Lauterbach K., Evers T. Treatment with sibutramine reduces the estimated risk of coronary heart disease: application of the Munster Heart Study Risk Equation (PROCAM). Am. J. Clin. Nutr. 2002, 75:91.
60. Marsh D.J., Hollopeter G., Kafer K.E., Palmiter R.D. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat. Med. 1998, 4:718-721.
61. O'Halloran D.J., Nikou G.C., Kreymann B., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man. J. Endocrinol. 1990, 126:169-173.
62. Pi-Sunyer F., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients-RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
63. Pi-Sunyer F., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients-RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
64. Redmon J.B., Raatz S.K., Reck K.P., Swanson J.E., Kwong C.A., Fan M.S., Thomas W., Bantle J.P. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care 2003, 26:2505-2511.
65. Rolls B.J., Shide D.J., Thorwart M.L., Ulbrecht J.S. Sibutramine reduces food intake in non-dieting women with obesity. Obes. Res. 1998, 6:1-11.
66. Rossi M., Choi S.J., Oshea D., Miyoshi T., Ghatei M.A., Bloom S.R. Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology 1997, 138:351-355.
67. Royal College of Physicians Clinical management of overweight and obese patients, with particular reference to the use of drugs 1998.
68. Sahu A., Kalra P.S., Kalra S.P. Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides 1988, 9:83-86.
69. Sjostrom L., Rissanen A., Andersen T., Boldrin M., Golay A., Koppeschaar H.P.F., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998, 352:167-172.
70. Stanley B.G., Leibowitz S.F. Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:3940-3943.
71. Stanley B.G., Chin A.S., Leibowitz S.F. Feeding and drinking elicited by central injection of neuropeptide Y: evidence for a hypothalamic site(s) of action. Brain. Res. Bull. 1985, 14:521-524.
72. Stanley B.G., Kyrkouli S.E., Lampert S., Leibowitz S.F. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986, 7:1189-1192.
73. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:5485-5489.
74. Thim L., Kristensen P., Larsen P.J., Wulft B.S. CART, a new anorectic peptide. [Review] [10 refs]. Int. J. Biochem. Cell Biol. 1998, 30:1281-1284.
75. Torgerson J.S., Hauptman J., Boldrin M.N., Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004, 27:155-161.
76. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M.B., Meeran K., et al. A role for glucagon-like peptide-1 in the central control of feeding. Nature 1996, 379:69-72.
77. Vaisse C., Clement K., Durand E., Hercberg S., Guy-Grand B., Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 2000, 106:253-262.
78. Verdich C., Flint A., Gutzwiller J.P., Naslund E., Beglinger C., Hellstrom P.M., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 2001, 86:4382-4389.
79. Wadden T.A., Berkowitz R.I., Womble L.G., Sarwer D.B., Phelan S., Cato R.K., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med. 2005, 353:2111-2120.
80. Weintraub M., Hasday J.D., Mushlin A.I., Lockwood D.H. A double-blind clinical-trial in weight control-use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med. 1984, 144:1143-1148.
81. Weintraub M., Rubio A., Golik A., Byrne L., Scheinbaum M.L. Sibutramine in weight control-a dose-ranging, efficacy study. Clin. Pharmacol. Ther. 1991, 50:330-337.
82. Weintraub M., Sundaresan P.R., Madan M., Schuster B., Balder A., Lasagna L., et al. Long-term weight control study, 1. (weeks 0 to 34)-the enhancement of behavior-modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin. Pharmacol. Ther. 1992, 51:586-594.
83. Wilding J., Van Gaal L., Rissanen A., Vercruysse F., Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int. J. Obes. 2004, 28:1399-1410.
84. Wilding J.P.H., Gilbey S.G., Bailey C.J., Batt R.A.L., Williams G., Ghatei M.A., et al. Increased neuropeptide Y messenger RNA and decreased neurotensin messenger RNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology 1993, 132:1939-1944.
85. Williams G., Cardoso H.M., Lee Y.C., Ball J.M., Ghatei M.A., Stock M.J., et al. Hypothalamic regulatory peptides in obese and lean Zucker rats. Clin. Sci. 1991, 80:419-426.
86. Wynne K., Park A.J., Small C.J., Patterson M., Ellis S.M., Murphy K.G., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects-A double-blind, randomized, controlled trial. Diabetes 2005, 54:2390-2395.
87. Zhang J.V., Ren P.G., Avsian-Kretchmer O., Luo C.W., Rauch R., Klein C., et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005, 310:996-999.